Given the elevated lifetime risk, many female BRCA1/2 and PALB2 germline pathogenic variant carriers (herein referred to as “carriers”) may wish to consider risk-reducing mastectomy (RRM) in order to prevent the development of breast cancer [1]. This evidence concerns the gene BRCA1 and breast cancer.